Cognitive functions in patients with episodic and chronic migraine
https://doi.org/10.33667/2078-5631-2019-1-2(377)-15-18
Abstract
Cognitive impairment (CN) is widespread in migraines, but very little has been studied. There is evidence that these violations are present in patients with episodic migraine (EM) during an attack and in the interictal period. The purpose of this work was to study the prevalence of objective CN in patients with EM and chronic migraine (CM) during the period of minimal or absent pain. Methods. The study involved 74 patients with CM and 42 patients with rare EM (no more than four days of headache per month) aged 18-59 years. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale. Evaluation of cognitive functions was performed using the Montreal MoCA cognitive function evaluation scale, the DSST digit test and the Ray test of the RAVLT hearing aural learning. Results. in the CM group, there was a decrease in the results of the DSST, MoCA tests and the RAVLT general memory index compared with patients with EM. in both groups, the value of the latter indicator did not reach the standard. in 38 % of patients with chronic respiratory infections, the result on the MoCA scale did not reach the lower limit of normal. The absence of interrelations between the results of tests for cognitive functions and the levels of anxiety and depression was revealed. Conclusion. in patients with EM and CM, objective CNs are observed. Preventive therapy of EM is needed to reduce the risk of chronicity and progression of CN.
About the Authors
N. V. Latysheva
First Moscow State Medical University n.a. I. M. Sechenov; Cephalgolog Co.- Headache and Vegetative Disorders Clinic n.a. academician Alexander Wayne - Clinical Base of First Moscow State Medical University n.a. I. M. Sechenov (Sechenov University), First Moscow State Medical University n.a. I. M. Sechenov
Russian Federation
Russian Federation
E. G. Filatova
First Moscow State Medical University n.a. I. M. Sechenov; Cephalgolog Co.- Headache and Vegetative Disorders Clinic n.a. academician Alexander Wayne - Clinical Base of First Moscow State Medical University n.a. I. M. Sechenov (Sechenov University), First Moscow State Medical University n.a. I. M. Sechenov
Russian Federation
Russian Federation
D. V. Osipova
First Moscow State Medical University n.a. I. M. Sechenov
Russian Federation
Russian Federation
A. B. Danilov
First Moscow State Medical University n.a. I. M. Sechenov
Russian Federation
Russian Federation
References
1. Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache. 2018 Dec 27. doi: 10.1111/head.13459.
2. Gil-Gouveia R, Oliveira AG, Martins IP. A subjective cognitive impairment scale for migraine attacks. The MIG-SCOG: Development and validation. Cephalalgia 2011; 31: 984-91. https://doi.org/10.1177/0333102411408359
3. Meyer JS, Thornby J, Crawford K, Rauch G. Reversible cognitive decline accompanies migraine and cluster headaches. Headache 2000; 40: 638-46. doi.org/10.1046/j. 1526-4610.2000.040008638.x
4. Quintela E, Castillo J, Munoz P, Pascual J. Premonitory and resolution symptoms in migraine: A prospective study in 100 unselected patients. Cephalalgia 2006; 26:1051-60. https://doi. org/10.1111/j.1468-2982.2006.01157.x
5. Gil-Gouveia R, Martins I. Clinical description of attack-related cognitive symptoms in migraine: A systematic review. Cephalalgia. 2018; 38 (7): 1335-50. doi. org/10.1177/0333102417728250
6. Huang L, Juan Dong H, Wang X, Wang Y, Xiao Zh. Duration and frequency of migraines affect cognitive function: evidence from neuropsychological tests and event-related potentials. J Headache Pain 2017; 18 (1): 54. doi.org/10.1186/s10194-017-0758-6
7. Costa A, Sansalone A, Squillace A, Vescio G, lannacchero R. 0007. Self-referred cognitive impairment in migraine patients. J Headache Pain. 2015; 16 (Suppl 1): A149. doi. org/10.1186/1129-2377-16-s1-a149
8. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629-808. doi.org/10.1177/0333102413485658
9. Geffen G, Moar KJ, O’hanlon AP, Clark CR, Geffen LB. Performance measures of 16 to 86-year-old males and females on the auditory verbal learning test. Clinical Neuropsychologist 1990; 4 (1): 45-63. doi. org/10.1080/13854049008401496
10. Nasreddine ZS, Phillips NA, Bédirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53 (4): 695-9. DOI: 10.1111/j.1532-5415.2005.53221.x
11. Munir F, Jones D, Leka S, Griffiths A. Work limitations and employer adjustments for employees with chronic illness. Int J Rehabil Res. 2005; 28: 111-7. doi. org/10.1097/00004 356-200506000-00003
12. Латышева Н. В., Филатова Е. Г., Осипова Д. В. Нарушения памяти и внимания у пациентов с хронической мигренью. Нервномышечные болезни. 2018; 8 (2): 10-6. doi. org/10.17650/2222-8721-2018-8-2-10-16
13. Magalhäes S, Hamdan A. The Rey Auditory Verbal Learning Test: normative data for the Brazilian population and analysis of the influence of demographic variables. Psychology & Neuroscience 2010:3 (1); 85-91. DOI: 10.3922/j. psns.2010.1.011
14. Spreen O, Strauss E. A compendium of neuropsychological tests: administration, norms, and commentary. 1998. New York: Oxford University Press.
15. Santangelo G, Russo A, Trojano L, Falco F, Marcuccio L, Siciliano M, Conte F, Garramone F, Tessitore A, Tedeschi G. Cognitive dysfunctions and psychological symptoms in migraine without aura: a cross-sectional study. J Headache Pain 2016; 17 (1): 76. doi. org/10.1186/s10194-016-0667-0
16. Kalaydjian A, Zandi PP, Swartz KL, Eaton WW, Lyketsos C. How migraines impact cognitive function: findings from the Baltimore ECA. Neurology 2007; 68 (17): 1417-24. doi. org/10.1212/01.wnl.0000268250.10171.b3
17. Raghuvanshi S, Pathak K. Recent advances in delivery systems and therapeutics of cinnarizine: a poorly water soluble drug with absorption window in stomach. J Drug Deliv. 2014; 2014: 479246. doi: 10.1155/2014/479246.
18. Bostani A1, Rajabi A, Moradian N, Razazian N, Rezaei M. The effects of cinnarizine versus sodium valproate in migraineprophylaxis. Int J Neurosci. 2013; 123 (7): 487-93. doi: 10.3109/00207454.2013.765419.
19. Teggi R, Colombo B, Gatti O, Comi G, Bussi M. Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study. Neurol Sci. 2015; 36 (10): 1869-73. doi: 10.1007/s10072-015-2270-6.
20. Тарасова С. В., Соколов А. Ю., Тумелевич Б. Ч., Амелин А. В., Скорормец А. А. Сравнительная эффективность Фезама и циннаризина у пациентов с мигренью. РМЖ. 2006; 14 (22): 1-4.
21. Щукин И. А., Лебедева А. В., Бурд С. Г., Фидлер М. С., Шихкеримов Р. К., Исмаилов А. М., Болотов А. В., Бельгушева М. Э. Хронические цереброваскулярные заболевания: вопросы диагностики и лечения. Consilium Medicum. 2016; 18 (2): 85-94.
22. Нодель М. Р. Лекарственный паркинсонизм: возможности минимизации риска. Нервные болезни. 2015; 3: 18-23.
23. Lin HL, Lin HC, Tseng YF, Chen SC, Hsu CY. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Eur J Clin Pharmacol. 2017; 73 (3): 365-371. doi: 10.1007/s00228-016-2181-3.
Review
For citations:
Latysheva N.V., Filatova E.G., Osipova D.V., Danilov A.B. Cognitive functions in patients with episodic and chronic migraine. Medical alphabet. 2019;1(2):15-18. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-2(377)-15-18
Views:
698
Email this article 